Intryx Therapeutics Receives IND Clearance of ITX-402 in Brain Neoplasms for a Phase 1/2a Pediatric Brain Tumor Trial

On November 17, 2026 Intryx Therapeutics, LLC (formerly known as NanOlogy, LLC) ("Intryx"), a clinical-stage oncology company leading the development of intratumoral cancer therapeutics enabled by its Purcision Platform Technology, reported the U.S. Food and Drug Administration clearance of an investigational new drug (IND) application for ITX-402 in brain neoplasms. The company plans to initiate TIGER-1, a Phase 1/2a pediatric clinical trial, to evaluate ITX-402 in diffuse midline glioma (DMG) including diffuse intrinsic pontine glioma (DIPG).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ITX-402 is a large surface area microparticle (LSAM) of cisplatin, a proven therapeutic, in suspension for stereotactic intratumoral delivery to brain tumors resulting in continuous concentrated local drug release over time.

The open-label dose-escalating Phase 1/2a single-arm trial (NCT07767110), titled Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response (TIGER-1), is designed to enroll up to 20 patients to evaluate safety, drug exposure, and clinical activity of ITX-402 in patients with confirmed DMG/DIPG following standard-of-care therapy.

"IND clearance of ITX-402 marks an important achievement in the fight against DMG/DIPG, one of the most challenging pediatric cancers to treat," said Intryx Chief Executive Officer David Arthur. "Our preclinical research demonstrated drug activity in DMG/DIPG models and the feasibility and safety of injecting ITX-402 into precise areas of the brain. We look forward to initiating this trial and the possibility of a new therapeutic option for children with this devastating disease."

Intryx is collaborating with WEP Clinical, Morrisville NC, as its clinical research organization to conduct the TIGER-1 clinical trial.

About Diffuse Midline Glioma including Diffuse Intrinsic Pontine Glioma

DMG/DIPG is a highly lethal inoperable brain tumor that afflicts approximately 350 children and their families each year in the United States. Median survival is less than one year and fewer than 2% of patients survive five years. Current treatment options including radiotherapy and dordaviprone offer limited benefits and a significant unmet need exists for newer therapies to improve quality of life and survival.

About Purcision Platform Technology

Purcision converts small molecules into large surface area microparticles (LSAMs) optimized for intratumoral delivery aimed at increasing solid tumor response without increasing systemic toxicity. LSAMs are comprised of 100% pure drug, with no excipients or coating agents, and feature a particle size designed for tumor retention, increased surface area for continuous concentrated local drug release over time, and reduced bulk density for homogeneity in suspension at time of use. Each new LSAM offers composition-of-matter patentability protecting these key regulatory specifications.

(Press release, Intryx Therapeutics, NOV 17, 2026, View Source [SID1234674857])

Onward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to Advance Clinical-Stage Oncology Pipeline

On November 17, 2026 Onward Therapeutics, Inc. ("Onward Therapeutics" or the "Company") reported that it has closed its NT$900 million (approximately US$28 million) Series B financing. The round was raised in two closings, the second of which took place in October 2026. It is the Company’s first capital increase in Taiwan since it completed its share exchange and moved its global headquarters from Switzerland to Taiwan in October 2025. Before the share exchange, the Company had raised a total of CHF 75.5 million (approximately US$90 million) in its previous rounds. Proceeds from the Series B will fund the Company’s clinical programs, the manufacturing of clinical supplies, and early-stage R&D.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Existing individual and institutional shareholders, including CDIB Capital Healthcare Ventures and Hong Kong Chlitina International, continued to support the Company in this round. New institutional investors include Beiley Biofund, Everbright Biofund, Test Rite International Co., Ltd., Grand Fortune Venture Capital, Hercules Bioventure Partners, MitoBitTech Venture, and Top Taiwan Venture Capital. A number of individual investors also joined the round.

Dr. C. Grace Yeh, Chairperson and CEO of Onward Therapeutics, said, "This financing, our first since establishing our global headquarters in Taiwan, allows us to advance our clinical programs while building our R&D presence here. We are grateful for the continued support of our existing shareholders and welcome our new investors. Many patients with difficult-to-treat or relapsed cancers still have limited treatment options. We aim to bring them new options through different types of cancer therapies."

Onward Therapeutics’ portfolio includes two clinical-stage programs (an innovative bispecific antibody and an allogeneic cell therapy) and two early-stage drug discovery programs.

OT-A201 is a tetravalent bispecific antibody designed to address complementary mechanisms of tumor immune evasion and potential resistance to existing therapies. In solid tumors, OT-A201 has completed monotherapy dose escalation and advanced to Phase 1b, where planned studies include indication-specific expansion cohorts and combination regimens. In hematologic malignancies, enrollment in the Phase 1a study is expected to be completed by the end of 2026. Preliminary clinical activity, including tumor responses and disease stabilization, has been observed across different cancer types with a manageable safety profile, supporting further clinical investigation.

OT-C001 is an off-the-shelf, allogeneic natural killer (NK) cell therapy derived from umbilical cord blood. It is being evaluated in combination with rituximab in a Phase 1 clinical trial in France for patients with diffuse large B-cell lymphoma (DLBCL) who have relapsed after, or are refractory to, prior CAR-T and T-cell engager therapies. Preliminary results indicate a favorable safety profile, and several cases of complete metabolic response have been observed. Enrollment and follow-up are ongoing.

Onward Therapeutics’ early-stage pipeline includes a small-molecule project in onco-metabolism (OT-S00X) and an antibody program against tumor-associated antigens (OT-A30X) with potential first-in-class characteristics.

Dr. Armand de Gramont, one of the Company’s three co-founders, was promoted from Chief Scientific Officer to President of R&D in April 2026. He oversees the Company’s overall R&D strategy and clinical development. "Our priority is to translate innovative science into meaningful clinical results. By focusing on indications where our therapies have the greatest potential to overcome treatment resistance, we aim to build a differentiated oncology pipeline to deliver new treatment options for patients," said Dr. de Gramont.

Onward Therapeutics has signed a listing advisory agreement with a securities firm and begun preparing to register on the Taipei Exchange’s Emerging Stock Board by the end of 2027. In addition, the Company plans to expand its team and start clinical trials in Taiwan, further strengthening its local R&D presence.

(Press release, Onward Therapeutics, NOV 17, 2026, View Source [SID1234674889])

OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidate

On November 17, 2026 OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, reported its manufacturing and supply partnership with Aura Biosciences, Inc. ("Aura") (NASDAQ: AURA), a biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers. OXB is supporting late-stage development and manufacturing activities for Aura’s lead virus-like drug conjugate candidate, belzupacap sarotalocan (bel-sar), as Aura advances the programme through Phase 3 development and prepares for potential future commercial supply. Aura recently announced the partnership and its manufacturing strategy in its Q3 corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Aura’s programme is being supported from OXB’s process and analytical development facility in Bedford, Massachusetts, and FDA-approved, commercial-scale viral vector manufacturing facility in Durham, North Carolina, which brings drug substance and fill and finish capabilities together on one site. OXB has initiated technical transfer in preparation for process performance qualification (PPQ) and commercial production. Together, these activities will support Aura’s manufacturing readiness for late-stage clinical development, potential future regulatory filings and commercialisation.

This partnership reflects OXB’s leading position in the space, drawing on more than 30 years of viral vector process development, analytical and GMP manufacturing experience into clinical and commercial stages.

Dr. Sebastien Ribault, Chief Business Officer of OXB, commented: "As Aura advances bel-sar through Phase 3 development, a well-characterised and robust manufacturing process is critical. OXB brings extensive experience supporting complex viral vector programmes through process characterisation, PPQ and towards commercialisation. Supporting this promising candidate from our site in Durham, North Carolina, gives Aura experienced late-stage process and manufacturing teams at a site built for commercial-scale production. This also represents an exciting opportunity for OXB to step into VDC manufacturing, an adjacent segment that sits close to our core viral vector expertise and this partnership demonstrates our ability to provide a world-class service offering in this area."

(Press release, Oxford BioMedica, NOV 17, 2026, View Source [SID1234674842])

Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer

On November 17, 2026 Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, and City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, reported the launch of an innovative Phase 1 clinical trial to explore a new combination therapy for patients battling metastatic colorectal cancer, particularly for those whose disease has resisted standard treatments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Colorectal cancer is the second deadliest cancer in the U.S., and current treatments don’t work for everyone. We urgently need to find new options, especially for the advanced stages of this challenging disease," said principal investigator Marwan G. Fakih, M.D., a City of Hope professor in the Department of Medical Oncology & Therapeutics Research and deputy director of City of Hope Comprehensive Cancer Center.

This year alone, an estimated 159,000 Americans will be diagnosed with colorectal cancer, and the disease will claim about 55,230 lives, according to the American Cancer Society.

City of Hope’s trial will enroll up to 36 patients to evaluate two experimental drugs, ivonescimab and muzastotug (ADG126)*, in the treatment of advanced microsatellite stable colorectal cancer. Ivonescimab activates the immune system’s T cells to attack cancer cells as it cuts off the blood supply to tumors, while ADG126 enhances the immune system’s ability to recognize and destroy cancer. The two drugs are expected to result in synergistic antitumor activity.

"Based on insights gleaned from past studies, we expect this powerful drug combination will result in more potent activation of the immune system within tumors, leading to potential tumor regression or death," Dr. Fakih said. "Our mission is to speed lifesaving care to patients by crafting a more effective therapy that enhances quality of life and boosts survival rates."

Physician-led innovation to reshape patient care

Investigator-initiated trials like this one are clinical studies designed by doctors or scientists rather than an industry sponsor. Fueled by researchers’ scientific curiosity, medical insight and dedication to patient-centered care, these trials provide independent, real-world data that can ignite therapeutic advances and shift clinical guidelines.

Dr. Fakih and his colleagues will initially evaluate the combination of ivonescimab and ADG126 in patients who progressed on prior systemic therapy and will determine the most optimal dosing combination based on safety and efficacy. Once the optimal dose is identified, they plan to move this combination earlier on in the treatment of metastatic colorectal cancer. Specifically, they will explore combining this immunotherapy combination with 5-FU, the backbone of chemotherapy treatments in colorectal cancer. Subsequently, they will add an additional chemotherapy drug, irinotecan, which is commonly used in the first-line and second-line treatment of metastatic colorectal cancer.

"We hope that the combination of immunotherapy with ivonescimab and ADG126 will work hand in hand with chemotherapy to improve further tumor shrinkage in advanced colorectal cancer," Dr. Fakih said. "The combination of ivonescimab, ADG126 and 5-FU has the potential to serve as a more effective maintenance therapy in metastatic colorectal cancer, deepening and maintaining responses to therapy. The combination of ivonescimab, ADG126, 5-FU and irinotecan has the potential to serve as a first-line treatment in metastatic colorectal cancer and improve further on the chances of remission, regression and duration of disease control."

Peter Luo, Ph.D., Chairman, CEO and President of R&D at Adagene, added, "This is the third clinical program to combine muzastotug or ADG126 with a next generation PD-1 bispecific with the goal of driving additional survival benefit for patients. This trial further validates and broadens the potential use of ADG126 as a foundational combination backbone to potentially drive more clinically meaningful survival benefits for patients".

"ADG126 is designed to activate preferentially in the tumor microenvironment, enabling CTLA-4 blockade while limiting on-target, off-tumor activity in healthy tissues. By combining this approach with complementary immune, angiogenic and cytotoxic mechanisms, the study will assess the safety and preliminary antitumor activity of these regimens. We value City of Hope’s leadership and clinical expertise in colorectal cancer."

Fighting a high risk of recurrence

Some 85% of colorectal cancer cases are classified as microsatellite stable (MSS), which has a higher risk of returning after treatment. Despite numerous clinical studies, no new therapies have outperformed existing treatments in halting growth.

Recent findings, however, have suggested promising new directions, including:

· Integrating ivonescimab and chemotherapy significantly improved results in a small trial of 22 people, with 82% of the patients responding positively.

· Blending two treatments — one targeting a protein called PD-1 and another targeting blood vessel growth (VEGFR) — helped patients whose colorectal cancer had not spread to the liver.

· Ivonescimab targets both PD-1 and VEGF, potentially enhancing effectiveness while reducing side effects. When paired with drugs that block PD-1, ADG126 boosted the immune system’s ability to combat cancer.

Building off these discoveries, Dr. Fakih and his team developed the current trial to investigate how combining ivonescimab and ADG126 affects patients with advanced colorectal cancer.

In integrating the approach with traditional chemotherapy, his work aims to pinpoint the safest dosage for new drug combinations and determine how long they combat cancer growth.

"The clock is ticking; we can’t afford to lose more patients to this devastating disease," Dr. Fakih said. "Our study is a crucial step forward in finding better approaches for fighting advanced colorectal cancer."

* Dr. Fakih is a paid consultant to Adagene, the owner of ADG126.

(Press release, Adagene, NOV 17, 2026, View Source [SID1234674872])

Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma

On November 17, 2026 Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, reported updated clinical data from the Phase 1/2 expansion study evaluating ozekibart (INBRX-109), an investigational tetravalent death receptor 5 (DR5) agonist, in combination with irinotecan and temozolomide (IRI/TMZ) in patients with relapsed or refractory Ewing sarcoma. The data will be presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The updated clinical data to be presented at CTOS underscore the deep activity and expanding reach of ozekibart in aggressive, difficult-to-treat bone and soft tissue sarcomas," said Mark Lappe, Chief Executive Officer of Inhibrx. "In relapsed or refractory Ewing sarcoma, achieving a 62.7% overall response rate, an 86.3% disease control rate, and clinically meaningful durability is particularly compelling in a population that has exhausted effective options. Based on these results, we intend to rapidly advance our plans with the goal of allowing patients access as soon as possible."

Ewing Sarcoma

As of the September 18, 2026, data cutoff, 60 patients (including 9 adolescent patients) were enrolled and treated with ozekibart plus IRI/TMZ, with 22 patients remaining on active treatment. Among the 51 response-evaluable patients, the combination demonstrated an overall response rate (ORR) of 62.7%, comprising 2 complete responses (CRs) and 30 partial responses (PRs). A total of 84.3% of response-evaluable patients (43/51) experienced measurable reduction in tumor size from baseline. An additional 12 patients achieved stable disease (SD), resulting in a Disease Control Rate (DCR) of 86.3%.

The median progression free survival (mPFS) was 6.0 months (95% CI: 4.6–7.4). Durable clinical benefit exceeding 6 months was observed in 18 patients (1 CR, 1 SD, 16 PRs), including 1 patient maintaining an ongoing PR for more than 2 years. At the cutoff date, 14 response-evaluable patients remained progression-free, including 2 patients with a PFS duration exceeding 12 months.

These data represent a meaningful improvement over historical benchmarks, such as irinotecan and temozolomide alone in relapsed or refractory Ewing sarcoma, which typically yield an ORR of approximately 15% to 30% and a mPFS of roughly 3 to 4 months.

The combination continued to demonstrate an acceptable and manageable safety profile consistent with the known cytotoxic toxicities of IRI/TMZ and DR5 agonism, with no evidence of unexpected cumulative hepatotoxicity.

The FDA accepted for filing our biologics license application for the potential approval of ozekibart in conventional chondrosarcoma. With approximately 300 new cases of Ewing sarcoma diagnosed each year in the U.S. and an estimated 2,500 individuals in the U.S. currently living with Ewing sarcoma, the need for novel therapeutic options in this underserved community is profound, and we look forward to discussing these results with the FDA.

Presentation Materials

Ewing Sarcoma Poster Details:

Title: Phase 1/2 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined with Irinotecan (I) and Temozolomide (T) in Adolescents and Adults with Ewing Sarcoma (EWS)
Session: Poster Presentation Session
Abstract Number: 2465416
Presenter: Varun Monga, M.D.
Date: Thursday, November 19, 2026
The poster materials will be made available in the "Events & Presentations" section of the Inhibrx Biosciences investor portal at inhibrxbiosciences.investorroom.com.

About ozekibart (INBRX-109)

Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. Ozekibart is engineered to optimize tumor-biased receptor clustering and activation without requiring secondary crosslinking, avoiding the severe hepatotoxicity observed with first-generation DR5-targeting agents.

(Press release, Inhibrx, NOV 17, 2026, View Source [SID1234674890])